Re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer-specific survival: A cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. in press. http://dx.doi.org/10.1016/j.eururo.2013.01.007.

European Urology

Volumn 64, Issue 1, 2013, Pages

  Cardwell, Chris R ^a   Suissa, Samy ^b   Murray, Liam J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; FOLLOW UP; HUMAN; LETTER; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84878840742     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.046     Document Type: Letter

References (3)

1. Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007.
2. S. Suissa Immortal time bias in pharmaco-epidemiology Am J Epidemiol 167 2008 492 499
3. L.E. Lévesque, J.A. Hanley, A. Kezouh, and S. Suissa Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes BMJ 340 2010 b5087